Emricasan is at phase II development for your treatment of chronic liver disease, including NASH fibrosis, underneath the ENCORE program.
Institutional s have recently traded in shares with the company. 00 target price for your company in a research directory Wednesday, November 9th.

Comments

Who Upvoted this Story